Was betrifft es? Warum ist das wichtig?

As an initial step and prior to risk evaluation, factors Critical-to-Quality (CtoQ) should be identified. Defining the CtoQ factors of the study, guarantees study efficiency as the focus remains on risks that threaten the:

 

As a second step risks are evaluated and prioritized.

 

Risk evaluation asks:

  • What is the likelihood that an error occurs?
  • The extent and threshold at which an error can be detected?
  • What is the expected impact of the error on CtoQ factors?

 

Risk prioritisation asks:

  • Based on the risk evaluation, how should a risk be prioritised? As a high-, medium-, or low- risk to the study?
  • How will risk-priority affect the requirement of risk control-measures?

Was muss ich befolgen?

As a SP-INV:

  • Identify and prioritize CtoQ factors that are critical to your study
  • Seek input from a broad range of stakeholders (e.g. study population representatives, data manager, statistician)
  • Identify risks that threaten the integrity of CtoQ factors
  • Evaluate risks based on likelihood of occurrence and detection, including impact

 

Prioritise risks according to their position in a REM diagram, with:

  • 1. High risk and high impact – top priority
  • 2. High impact and low risk – medium priority
  • 3. Low impact and high risk – medium priority
  • 4. Low impact and low risk – low priority

 

Document risk evaluation and prioritisation in a Risk Assessment Form (RAF)

 

As a SP-INV, plan for study conduct on how to:

  • Control risks to CtoQ factors (i.e. control-measure adjustments may become necessary or new / unanticipated risks may arise)
  • Assess the efficacy and applicability of risk control-measures
  • Retain oversight and document CtoQ management

Mehr

Irrespective of risk position in the REM, additional individual risk ratings might become necessary to decide what resources are most advisable to invest in (e.g. study staff, infrastructure, budget).

Wo kann ich Hilfe anfordern?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guidelines

  • 3.10 Quality management
  • 3.10.1.2 Risk evaluation
  • 3.11.4.3 Monitoring plan and CtoQ
  • 6.2 Factors critical to quality
  • 7.3 Management of CtoQ factors

ICH E8(R1) – see in particular guidelines

  • 3. Designing quality into clinical studies

ISO 31000 (access liable to costs) – see in particular section

  • Risk management: Principles and guidelines

Documents

Abkürzungen
  • CtoQ – Critical-to-Quality
  • CTU – Clinical Trials Unit
  • ICH – International Council for Harmonisation
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ISO – International Organization for Standardization
  • REM - Risk Evaluation Matrix
  • SP-INV – Sponsor-Investigator
Development ↦ Quality and Risk ↦ Study Risk Management ↦ Risk Evaluation and Prioritisation
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Development ↦ Quality and Risk ↦ Study Risk Management ↦ Risk Evaluation and Prioritisation